**Specifications table**TableSubject area*Biology, Endocrinology*More specific subject area*Metabolic regulation in the liver*Type of data*RNA-seq data tables and figures*How data were acquired*RNA-Sequencing, Ingenuity Pathway Analysis*Data format*Normalized, filtered and analyzed data; Bioinformatic prediction*Experimental factors*Liver transcriptome profile in Esr1 knockout (Esr1-/-) male rats*Experimental features*Liver tissues were collected from 10-week-old wild type and Esr1-/- male rats. Total RNA was isolated, and cDNA-libraries were prepared for RNA-sequencing. RNA-seq raw data reads were analyzed using CLC Genomics Workbench. Differentially expressed genes were further analyzed for their involvement in carbohydrate and lipid metabolism by IPA.*Data source location*A basic science laboratory at the University of Kansas Medical Center, Kansas City, KS, USA.*Data accessibility*Raw data have not yet been submitted to any public repository.*Related research article*V. Khristi, A. Ratri, S. Ghosh, S. Borosha, E. Dai, R. Roy, et al., Disruption of ESR1 alters the expression of genes regulating hepatic lipid and carbohydrate metabolism in male rats, Endocrinology (2018), Under review*[@bib1].

**Value of the data**•This data article provides liver transcriptomic analyses of *Esr1-/-* male rats.•Pathway analyses of the differentially expressed genes in the *Esr1*-/- liver show their involvement in carbohydrate and lipid metabolism.•Differentially expressed genes are also linked to development of obesity, hepatic steatosis, and other liver diseases.

1. Data {#s0005}
=======

In this data article, we present analyzed RNA-seq data showing the differentially expressed genes in the *Esr1-/-* male liver ([Table S1](#s0060){ref-type="sec"}). Bioinformatic analyses show that these differentially expressed genes are linked to pathways of carbohydrate metabolism ([Table 1](#t0005){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}), lipid metabolism ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}) and hepatic diseases including hepatic steatosis, necrosis of the liver, and obesity ([Fig. 3](#f0015){ref-type="fig"}).Fig. 1Mechanistic diagram of selected pathways involved in the carbohydrates metabolism.Fig. 1Fig. 2Mechanistic diagram of selected pathways involved in the synthesis and oxidation of lipids.Fig. 2Fig. 3Mechanistic diagram of genes involved in hepatic steatosis, necrosis of the liver, and obesity.Fig. 3

2. Experimental design, materials, and methods {#s0010}
==============================================

2.1. *Esr1* knockout rats {#s0015}
-------------------------

The Holtzman Sprague-Dawley (HSD) *Esr1*-mutant rat model was generated by targeted deletion of exon 3 in the *Esr1* gene [@bib2]. Deletion of exon 3 caused a frameshift and null mutation in the ESR1 coding sequence [@bib2]. All animals were screened for the presence of the mutation by PCR using tail-tip DNA samples (REDExtract-N-Amp Tissue PCR Kit, Sigma-Aldrich) and primers targeting the flanking intron sequences [@bib2]. All procedures were performed in accordance with the protocols approved by the University of Kansas Medical Center Animal Care and Use Committee.

2.2. Sample collection from wild type and *Esr1-/-* rats {#s0020}
--------------------------------------------------------

Liver tissues were collected from 10 to 12-week-old *Esr1*-/- and age matched wild type male rats. The tissue samples were collected immediately after euthanization, cut into small species, snap frozen in liquid nitrogen, and stored at −80 °C until they were processed for RNA extraction. Total RNA from liver tissues was extracted using TRI Reagent (Millipore-Sigma) following the manufacturer׳s instructions. RNA quality was assessed using the Agilent Bioanalyzer and samples with a RIN score ≥ 9 were included in the RNA-seq library preparation.

2.3. Library preparation and RNA-sequencing {#s0025}
-------------------------------------------

The library preparation and sequencing of RNA was performed at the Genome Sequencing facility of the University of Kansas Medical Center. Five hundred nanogram of liver total RNA was used for the RNA-seq library preparation. Libraries were prepared using a TruSeq Stranded mRNA kit (Illumina) following the manufacturer׳s instructions. Briefly, mRNA was enriched from total RNA by oligo-dT magnetic beads, purified, and chemically fragmented. The first strand of cDNA was synthesized using random hexamer primers and reverse transcriptase. Then, double stranded (ds) cDNA was generated by removing the RNA template and synthesizing a replacement strand, incorporating dUTP in place of dTTP. ds cDNA was purified from the second strand reaction mix by AMPure XP beads (Beckman Coulter). The cDNA ends were blunted and poly (A) tails were added to the 3' ends. Finally, after ligation of indexing adaptors (Illumina), the suitable DNA fragments were selected for PCR amplification for 15 cycles. Three replicate cDNA libraries were prepared for each of the wild type and *Esr1-/-* groups and sequenced on an Illumina HiSeq. 2500 platform.

2.4. Analyses of the RNA-sequencing data {#s0030}
----------------------------------------

RNA-seq data were analyzed using CLC Genomics Workbench (Qiagen Bioinformatics). Raw reads of RNA-seq were analyzed as described in a previous publication [@bib3]. Clean reads were obtained by removing low quality reads through trimming. High quality reads of liver RNA-seq were aligned to the *Rattus norvegicus* genome (Rn6, downloaded from NCBI database). RNA-seq data were mapped with the following parameters: (a) maximum number of allowed mismatches was set at 2; (b) minimum length and similarity fraction were set at 0.8; and (c) minimum number of hits per read was set at 10. Gene expression values were reported as RPKM (Reads Per Kilobase of transcript per Million mapped reads) [@bib4]. In this study, gene expression values showing an absolute fold change of 2 with *p-*value ≤ 0.05 were considered differentially expressed. A total of 618 genes were differentially expressed in *Esr1-/-* liver, 410 downregulated and 208 upregulated ([Table S1](#s0060){ref-type="sec"}).

2.5. Pathway analysis of differentially expressed genes in *Esr1-/-* liver {#s0035}
--------------------------------------------------------------------------

Differentially expressed genes in the *Esr1-/-* liver were subjected to Ingenuity Pathway Analysis (IPA; Qiagen Bioinformatics). The pathways and genes involved in carbohydrate and lipid metabolism are listed in [Tables 1](#t0005){ref-type="table"} and [2](#t0010){ref-type="table"}. The selected pathways from carbohydrate metabolism shown elevated glucose level in *Esr1-/-* rats shown in [Fig. 1](#f0005){ref-type="fig"}. In lipid metabolism, synthesis of lipid and concentration of triglyceride were increased in *Esr1-/-* rats. In contrast, oxidation of lipid and fatty acid was lower in *Esr1-/-* rats ([Fig. 2](#f0010){ref-type="fig"}). The genes involved in hepatic steatosis and obesity are shown in [Fig. 3](#f0015){ref-type="fig"}.Table 1List of pathways involved in 'Carbohydrate metabolism'.Table 1**Diseases or functions annotation*****p*****-valuePredicted activation stateActivation z-scoreMolecules\# Molecules**Gluconeogenesis0.00000000.343ACOT13, ALDH1A1, CRY1, FGF21, G6PC, GCK, IGFBP1, NR0B2, PPARA9Concentration of D-glucose0.00000010.69ALDH1A1, CIDEA, ESR1, FGF21, FMO5, G6PC, GCK, GDF15, IGFBP1, Mt1, MYC, NR0B2, ONECUT1, PPARA, THRA15Metabolism of D-glucose0.00000011G6PC, GCK, IGFBP1, MYC, ONECUT1, PPARA, SORD7Synthesis of D-hexose0.00000231.735ALDH1A1, DUSP6, FGF21, GCK, MYC, PPARA, SORD7Quantity of carbohydrate0.0000024Increased2.257ALDH1A1, CD14, CIDEA, ESR1, FGF21, FMO5, G6PC, GCK, GDF15, Gulo, IGFBP1, Mt1, MYC, NR0B2, ONECUT1, PPARA, THRA17Homeostasis of D-glucose0.0000017ACOT13, CIDEA, CRY1, FGF21, FMO5, G6PC, GCK, PPARA, SLC27A5, THRA10Transport of carbohydrate0.0000100.478ABCC2, CD14, ESR1, FGF21, G6PC, GCK, MAP2K6, MYC, SLC1A29Synthesis of D-glucose0.00000231.735ALDH1A1, DUSP6, FGF21, GCK, MYC, PPARA6Quantity of glucose-6-phosphate0.000032G6PC, GCK, MYC3Regulation of D-glucose0.0000024FGF21, MYC, PPARA3Utilization of D-glucose0.000075GCK, MYC, PPARA, THRA4Transport of monosaccharide0.0001190.555ESR1, FGF21, G6PC, GCK, MAP2K6, MYC, SLC1A27Phosphorylation of D-glucose0.00021G6PC, GCK2Metabolism of glucose-6-phosphate0.0000057G6PC, GCK2Transport of D-glucose0.000440.555ESR1, FGF21, GCK, MAP2K6, MYC, SLC1A26Quantity of glycogen0.00001001.172FGF21, G6PC, GCK, MYC, PPARA5Synthesis of carbohydrate0.0005831.809ALDH1A1, DUSP6, FGF2, G6PC, GCK, Gulo, IGFBP1, MYC, NR1D1, PPARA, SORD11Gluconeogenesis of hepatocytes0.0000268ALDH1A1, NR0B22Import of D-glucose0.00140ESR1, FGF21, MYC, SLC1A24Metabolism of carbohydrate0.00003201.483ALDH1A1, CYP2E1, DUSP6, FGF21, G6PC, GCK, Gulo, IGFBP1, MYC, NR1D1, ONECUT1, PPARA, SORD13Uptake of carbohydrate0.002050.306ABCC2, CD14, FGF21, G6PC, GCK, MYC, PPARA, SLC1A28Synthesis of glycogen0.0000560G6PC, GCK, IGFBP1, NR1D14Quantity of lactic acid0.00214GCK, MYC, PPARA3Production of lactic acid0.0000750GCK, MYC, PPARA3Table 2List of pathways involved in 'Lipid metabolism'.Table 2**Diseases or functions annotation*****p*****-valuePredicted activation stateActivation z-scoreMolecules\# Molecules**Synthesis of terpenoid0.00000001.169AKR1C1/AKR1C2, AKR1D1, ALDH1A1, BCO1, CRY1, CYP7B1, CYP8B1, ESR1, G6PC, GDF15, GSTA3, HDC, HSD17B2, NR1D1, POLG, PPARA, SLC27A5, SULT1E118Metabolism of terpenoid0.00000000.342ADH7, AKR1C1/AKR1C2, AKR1D1, ALDH1A1, BCO1, CYP2E1, CYP7B1, CYP8B1, ESR1, G6PC, GSTA3, HDC, HSD11B2, HSD17B2, NR0B2, SLC27A5, SULT1E1, UGT2B1118Quantity of steroid0.00000000.547ABCC2, ACOT13, BCO1, CRY1, CYP8B1, ESR1, FGF21, FMO5, G6PC, GCK, Gulo, HSD11B2, IL33, JUN, NFIL3, NR0B2, POLG, PPARA, SLC1A2, SULT1E1, THRA, ZBTB1622Concentration of lipid0.00000001.111ABCC2, ACOT13, ALDH1A1, BCO1, CD14, CIDEA, CRY1, CYP2E1, CYP8B1, EFNA5, ESR1, FGF21, FMO5, G6PC, GCK, Gulo, HSD11B2, IL33, JUN, MYC, NFIL3, NR0B2, ONECUT1, POLG, PPARA, SLC1A2, SULT1E1, THRA, ZBTB1629Synthesis of steroid0.00000000.601AKR1C1/AKR1C2, AKR1D1, CRY1, CYP7B1, CYP8B1, ESR1, G6PC, GDF15, GSTA3, HDC, HSD17B2, NR1D1, POLG, PPARA, SLC27A5, SULT1E116Steroid metabolism0.0000000−0.594AKR1C1/AKR1C2, AKR1D1, CYP2E1, CYP7B1, CYP8B1, ESR1, G6PC, GSTA3, HDC, HSD11B2, HSD17B2, NR0B2, SLC27A5, SULT1E1, UGT2B1115Concentration of cholesterol0.00000001.352ACOT13, BCO1, CYP8B1, ESR1, FGF21, FMO5, G6PC, GCK, Gulo, IL33, JUN, NFIL3, NR0B2, PPARA, SLC1A2, THRA16Synthesis of lipid0.0000000Increased2.092AKR1C1/AKR1C2, AKR1D1, ALDH1A1, BCO1, CD14, CRY1, CYP2E1, CYP7B1, CYP8B1, ELOVL6, ESR1, G6PC, GDF15, GSTA3, HDC, HSD17B2, IL33, MYC, NR0B2, NR1D1, POLG, PPARA, SLC27A5, SULT1E124Homeostasis of lipid0.0000000AKR1C1/AKR1C2, CIDEA, CYP7B1, CYP8B1, FGF21, G6PC, GCK, Mt1, NR0B2, NR1D1, NR1D2, PPARA12Oxidation of lipid0.0000000−0.47AKR1C1/AKR1C2, ALDH1A1, BDH2, CYCS, CYP2E1, ESR1, FGF21, HSD17B2, MYC, NR0B2, PPARA, THRA12Synthesis of bile acid0.0000000−0.132AKR1D1, CYP7B1, CYP8B1, NR1D1, PPARA, SLC27A56Concentration of acyl glycerol0.000001.388ACOT13, BCO1, CIDEA, ESR1, FGF21, FMO5, G6PC, GCK, JUN, MYC, NFIL3, NR0B2, ONECUT1, PPARA, THRA15Concentration of triacylglycerol0.000001.651ACOT13, BCO1, CIDEA, ESR1, FGF21, FMO5, G6PC, GCK, JUN, MYC, NFIL3, NR0B2, ONECUT1, PPARA14Uptake of cholesterol0.00001580AKR1C1/AKR1C2, CYP8B1, ESR1, NR0B2, PPARA5Concentration of bile acid0.000019ABCC2, CYP8B1, ESR1, NR0B24Quantity of ketone body0.0000334ACOT13, FGF21, GCK, PPARA4Inactivation of glucocorticoid0.0000352AKR1D1, HSD11B22Inactivation of lipid0.0000566AKR1D1, HSD11B2, SULT1E13Secretion of lipid0.00007720.927ABCC2, CIDEA, ESR1, HSD17B2, MAP2K6, NFIL3, PPARA, SULT1E18Absorption of cholesterol0.0000842AKR1C1/AKR1C2, CYP8B1, NR0B2, PPARA4Uptake of lipid0.000206−0.7AKR1C1/AKR1C2, CD14, CYP8B1, ESR1, NR0B2, PPARA, SLC27A57Production of ketone body0.000348FGF21, GCK2Metabolism of retinoid0.000453ADH7, ALDH1A1, BCO1, CYP2E14Concentration of fatty acid0.0004631.773ACOT13, CIDEA, CYP2E1, EFNA5, FGF21, G6PC, GCK, MYC, PPARA9Synthesis of ketone body0.00052PPARA, SLC27A52Metabolism of triacylglycerol0.000537ALDH1A1, CYP2E1, G6PC, NR0B2, PPARA5Abnormal quantity of lipid0.00055ACOT13, CYP8B1, ESR1, FGF21, GCK, NR0B26Hydroxylation of lipid0.000607CYP2E1, CYP4A22, CYP7B13Conversion of lipid0.0006220.905AKR1C1/AKR1C2, CYP2E1, HSD11B2, HSD17B2, Mt1, PPARA6Metabolism of sterol0.000856AKR1D1, CYP7B1, CYP8B1, HSD17B2, NR0B25Regulation of lipid0.00138FGF21, HSD11B2, PPARA3Modification of long-chain acyl-coenzyme A0.00154ELOVL6, PPARA2Activation of lipid0.00161FGF21, HSD11B2, SLC27A53Synthesis of sterol0.001831CYP7B1, CYP8B1, HDC, PPARA4Hydroxylation of fatty acid0.00187CYP2E1, CYP4A222Transport of lipid0.002090.386ABCC2, AKR1C1/AKR1C2, CD14, GDF15, IL33, PPARA, SLC27A57Fatty acid metabolism0.002770.767ABCC2, AKR1C1/AKR1C2, CD14, CYP2E1, CYP4A22, DBP, ELOVL6, GDF15, IL33, MYC, PPARA, SLC27A512Abnormal quantity of bile salt0.00306CYP8B1, NR0B22Uptake of bile salt0.00306NR0B2, PPARA2Metabolism of bile acid0.00352AKR1C1/AKR1C2, SLC27A52Regulation of steroid0.00352HSD11B2, PPARA2Homeostasis of bile salt0.00452CYP8B1, NR0B22Homeostasis of cholesterol0.005AKR1C1/AKR1C2, CYP7B1, G6PC, NR1D14Conjugation of lipid0.00506SLC27A5, UGT2B112Transport of steroid0.00529−0.106ABCC2, AKR1C1/AKR1C2, GDF15, IL33, PPARA5Metabolism of cholesterol0.00531AKR1D1, CYP7B1, CYP8B1, NR0B24

3. Statistical analysis {#s0040}
=======================

RNA-sequencing included three cDNA libraries in each group. Each library was prepared from pooled total RNA of two individual rats. Differentially expressed genes were identified by using CLC Genomics Workbench as described in a previous publication [@bib5].

Transparency document. Supplementary material {#s0050}
=============================================

Supplementary material.

Appendix A. Supplementary material {#s0060}
==================================

Supplementary material.
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